Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)
Study Details
Study Description
Brief Summary
This is a single-dose, randomized, cross-sectional comparison study examining the relative safety and resulting blood level profiles after administration of a new boceprevir tablet formulation versus its current capsule formulation for treatment of chronic hepatitis C. In Part 1 of the study participants will receive boceprevir tablets and capsules under fed conditions. In Part 2 of the study a new group of participants will receive boceprevir tablets and capsules under fasted conditions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Boceprevir Tablets then Capsules (fed) Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition. |
Drug: boceprevir
Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Other Names:
|
| Experimental: Boceprevir Capsules then tablets (fed) Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition. |
Drug: boceprevir
Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Other Names:
|
| Experimental: Boceprevir Tablets then Capsules (fasted) Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast. |
Drug: boceprevir
Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Other Names:
|
| Experimental: Boceprevir Capsules then Tablets (fasted) Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast. |
Drug: boceprevir
Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Area Under the Concentration Curve (AUC) From Hour 0 to the Final Quantifiable Sample (AUCtf) for Boceprevir Tablets Versus Capsules in Fed State [Predose through 72 hours post-dose]
AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve.
- Maximum Plasma Concentration (Cmax) of Boceprevir Tablets Versus Capsules in Fed State [Predose through 72 hours post-dose]
Cmax is the highest plasma drug concentration observed on the plasma concentration-time curve.
- AUCtf for Boceprevir Tablets Versus Capsules in Fasted State [Predose through 72 hours post-dose]
AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve.
- Cmax of Boceprevir Tablets Versus Capsules in Fasted State [Predose through 72 hours post-dose]
Cmax is the highest plasma drug concentration observed on the plasma concentration-time curve.
- AUC From Hour 0 to Infinity (AUCinf) in Fed State [Predose through 72 hours post-dose]
AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve.
- AUCinf in Fasted State [Predose through 72 hours post-dose]
AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve.
- Half Life (t1/2) of Boceprevir in Fed State [Predose through 72 hours post-dose]
T1/2 is the time required for a given drug concentration to decrease by 50%.
- t1/2 Boceprevir in Fasted State [Predose through 72 hours post-dose]
T1/2 is the time required for a given drug concentration to decrease by 50%.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subjects must be willing to give written informed consent for the trial and able to adhere to dose and visit schedules.
-
Subjects must be willing to give written informed consent for pharmacogenetic
testing, and able to adhere to applicable visit schedules.
- Subjects of either gender and of any race between the ages of 18 and 65
years, inclusive, having a Body Mass Index (BMI) between 18 and 32,
inclusive. BMI = weight (kg)/height (m)^2. (Individuals with values outside (or
indicate lower or higher) of these ranges may be enrolled if clinically
acceptable to the investigator and sponsor.)
-
Subjects' clinical laboratory tests (complete blood count [CBC], blood chemistry, and urinalysis) must be within normal limits or clinically acceptable to the investigator and within an allowed expanded range supplied by sponsor. However, subject's liver function test results (ie, aspartate aminotransferase [AST], alanine aminotransferase [ALT]) must not be elevated above normal limits at Screening and on Day -1. No rescreening of liver function tests will be allowed.
-
Subjects must be free of any clinically significant disease that would interfere with the study evaluations.
-
The Screening 12 lead electrocardiogram [ECG] conduction intervals must be within gender specific normal range (e.g, ECG QTcB,measure in males ≤430 msec and QTcB measure in females ≤450 msec, PR interval ≤200 msec).
-
Vital sign measurements (taken after ~3 minutes in a sitting position) must be
within the following ranges: (Individuals with values outside of these ranges
may be enrolled if clinically acceptable to the investigator and sponsor.)
-
oral body temperature, between 35.0°C and 37.5°C
-
systolic blood pressure, 90 to 140 mm Hg
-
diastolic blood pressure, 45 to 90 mm Hg
-
pulse rate, 40 to 100 bpm
- Female subjects must be:
- postmenopausal (defined as 12 months with no menses, age > 40
years and with a follicle-stimulating hormone [FSH] level of >40 u/mL, and serum E2 < 73 pmol/L), or
- surgically sterilized at least 3 months prior to baseline (eg, documented
hysterectomy or tubal ligation), or
- premenopausal and if unsterilized must have used a medically
accepted method of contraception for 3 months (or abstained from
sexual intercourse) prior to the screening period, and agree to use a
medically accepted method of contraception during the trial (including
the screening period prior to receiving trial medication) and for
2 months after stopping the trial medication. An acceptable method of
contraception includes one of the following:
- stable oral, transdermal, injectable, or sustained-release vaginal
hormonal contraceptive regimen without breakthrough uterine
bleeding for 3 months prior to Screening; in addition, during
study use of condom and/or spermicide (when marketed in the
country).
- intrauterine device (inserted at least 2 months prior to Screening
visit); in addition, during study use of condom and/or spermicide
(when marketed in the country).
- condom (male or female) with spermicide (when marketed
within the country),
- diaphragm or cervical cap with spermicide (when marketed
within the country) and condom (male),
- Non-vasectomized men must agree to use a condom with spermicide or abstain from sexual intercourse, during the trial and for 1 month after stopping the medication.
Exclusion Criteria:
- Female subjects who are pregnant, intend to become pregnant (within
3 months of ending the study), or are breastfeeding.
-
Subjects who, in the opinion of the investigator, will not be able to participate optimally in the study.
-
Any surgical or medical condition which might significantly alter the
absorption, distribution, metabolism or excretion of any drug. The investigator
should be guided by evidence of any of the following, and be discussed with
the sponsor prior to enrollment into the trial:
- history or presence of inflammatory bowel disease, ulcers,
gastrointestinal or rectal bleeding;
- history of major gastrointestinal tract surgery such as gastrectomy,
gastroenterostomy, or bowel resection;
-
history of pancreatic injury or pancreatitis;
-
history or presence of liver disease or liver injury;
-
history or presence of impaired renal function as indicated by clinically
significant elevation in creatinine, blood urea nitrogen [BUN]/urea, urinary albumin, or
clinically significant urinary cellular constituents ; or
- history of urinary obstruction or difficulty in voiding.
- Subject who has a history of any infectious disease within 4 weeks prior to
drug administration that in the opinion of the investigator, affects the subject's ability to participate in the trial.
- Subjects who are positive for hepatitis B surface antigen, hepatitis C
antibodies or human immunodeficiency virus [HIV].
- Subjects who have a positive screen for drugs with a high potential for abuse
(during the Screening period or clinical conduct of the trial).
- Subjects with a history of psychiatric or personality disorders that in the
opinion of the investigator and sponsor, affects the subject's ability to
participate in the trial.
-
Subjects with a history of alcohol or drug abuse in the past 2 years.- Subjects who have donated blood in the past 60 days.
-
Subjects who have previously received boceprevir.
-
Subjects who are currently participating in another clinical study or have
participated in a clinical study (e.g., laboratory or clinical evaluation) within 30 days of baseline.
- Subjects who are part of the study staff personnel or family members of the
study staff personnel.
- Subjects who have demonstrated allergic reactions (eg, food, drug, atopic
reactions or asthmatic episodes) which, in the opinion of the investigator and
sponsor, interfere with their ability to participate in the trial.
- Subjects who smoke more than 10 cigarettes or equivalent tobacco use per
day.
-
Subjects who have a history of malignancy.
-
Subjects who have received any prohibited treatment (prescription and non prescription medication except acetaminophen, potent inhibitors and inducers of cytochrome P3A [CYP3A4], or vitamins and herbals) more recently than the indicated washout period prior to Randomization which, in the opinion of the investigator and sponsor, interferes with their ability to participate in the trial.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Merck Sharp & Dohme LLC
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- P06992
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Boceprevir Tablets Then Capsules ( Fed) | Boceprevir Capsules Then Tablets ( Fed) | Boceprevir Tablets Then Capsules (Fasted) | Boceprevir Capsules Then Tablets (Fasted) |
|---|---|---|---|---|
| Arm/Group Description | Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition. | Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition. | Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast and then 4 days later will receive a single dose of boceprevir capsules, orally, following and overnight fast. | Participants will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast and then 4 days later will receive a single dose of boceprevir tablets, orally, following and overnight fast. |
| Period Title: Period 1, Fed (Part 1) | ||||
| STARTED | 30 | 30 | 0 | 0 |
| COMPLETED | 30 | 30 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 |
| Period Title: Period 1, Fed (Part 1) | ||||
| STARTED | 30 | 30 | 0 | 0 |
| COMPLETED | 30 | 30 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 |
| Period Title: Period 1, Fed (Part 1) | ||||
| STARTED | 0 | 0 | 59 | 58 |
| COMPLETED | 0 | 0 | 59 | 58 |
| NOT COMPLETED | 0 | 0 | 0 | 0 |
| Period Title: Period 1, Fed (Part 1) | ||||
| STARTED | 0 | 0 | 59 | 58 |
| COMPLETED | 0 | 0 | 58 | 58 |
| NOT COMPLETED | 0 | 0 | 1 | 0 |
Baseline Characteristics
| Arm/Group Title | Boceprevir Tablets Then Capsules (Fed) | Boceprevir Capsules Then Tablets (Fed) | Boceprevir Tablets Then Capsules (Fasted) | Boceprevir Capsules Then Tablets (Fasted) | Total |
|---|---|---|---|---|---|
| Arm/Group Description | Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition. | Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition. | Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast and then 4 days later will receive a single dose of boceprevir capsules, orally, following and overnight fast. | Participants will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast and then 4 days later will receive a single dose of boceprevir tablets, orally, following and overnight fast. | Total of all reporting groups |
| Overall Participants | 30 | 30 | 59 | 58 | 177 |
| Age (Count of Participants) | |||||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
30
100%
|
30
100%
|
59
100%
|
58
100%
|
177
100%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
0
0%
|
0
0%
|
| Sex: Female, Male (Count of Participants) | |||||
| Female |
10
33.3%
|
18
60%
|
27
45.8%
|
39
67.2%
|
94
53.1%
|
| Male |
20
66.7%
|
12
40%
|
32
54.2%
|
19
32.8%
|
83
46.9%
|
Outcome Measures
| Title | Area Under the Concentration Curve (AUC) From Hour 0 to the Final Quantifiable Sample (AUCtf) for Boceprevir Tablets Versus Capsules in Fed State |
|---|---|
| Description | AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve. |
| Time Frame | Predose through 72 hours post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is per protocol; all available data are included in the model. No imputation is used for missing data. |
| Arm/Group Title | Boceprevir Tablets (Fed) | Boceprevir Capsules (Fed) |
|---|---|---|
| Arm/Group Description | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. |
| Measure Participants | 60 | 60 |
| Geometric Mean (90% Confidence Interval) [ng*hr/mL] |
7385
|
6644
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Boceprevir Tablets (Fed) |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Non-Inferiority or Equivalence | |
| Comments | Comparison of boceprevir tablet versus capsule used a mixed-effects model with fixed effects for formulation, sequence, and period, and a random effect for participant within sequence. The geometric mean ratio (GMR) of boceprevir tablet to boceprevir capsule is presented with two-sided 90% CIs. Equivalence of formulations was signified by the GMR falling within prespecified bioequivalence bounds. | |
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Least Squares Geometric Mean Ratio |
| Estimated Value | 1.11 | |
| Confidence Interval |
(2-Sided) 90% 1.07 to 1.15 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Maximum Plasma Concentration (Cmax) of Boceprevir Tablets Versus Capsules in Fed State |
|---|---|
| Description | Cmax is the highest plasma drug concentration observed on the plasma concentration-time curve. |
| Time Frame | Predose through 72 hours post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is per protocol; all available data are included in the model. No imputation is used for missing data. |
| Arm/Group Title | Boceprevir Tablets (Fed) | Boceprevir Capsules (Fed) |
|---|---|---|
| Arm/Group Description | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. |
| Measure Participants | 60 | 60 |
| Geometric Mean (90% Confidence Interval) [ng*hr/mL] |
2161
|
1515
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Boceprevir Tablets (Fed), Boceprevir Capsules (Fed) |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Non-Inferiority or Equivalence | |
| Comments | Comparison of boceprevir tablet versus capsule used a mixed-effects model with fixed effects for formulation, sequence, and period, and a random effect for participant within sequence. The geometric mean ratio (GMR) of boceprevir tablet to boceprevir capsule is presented with two-sided 90% CIs. Equivalence of formulations was signified by the GMR falling within prespecified bioequivalence bounds. | |
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Least Squares Geometric mean ratio |
| Estimated Value | 1.43 | |
| Confidence Interval |
(2-Sided) 90% 1.32 to 1.54 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | AUCtf for Boceprevir Tablets Versus Capsules in Fasted State |
|---|---|
| Description | AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve. |
| Time Frame | Predose through 72 hours post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is per protocol; all available data are included in the model. No imputation is used for missing data. |
| Arm/Group Title | Boceprevir Tablets (Fasted) | Boceprevir Capsules (Fasted) |
|---|---|---|
| Arm/Group Description | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. |
| Measure Participants | 117 | 117 |
| Geometric Mean (90% Confidence Interval) [ng*hr/mL] |
4329
|
3935
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Boceprevir Tablets (Fed), Boceprevir Capsules (Fed) |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Non-Inferiority or Equivalence | |
| Comments | Comparison of boceprevir tablet versus capsule used a mixed-effects model with fixed effects for formulation, sequence, and period, and a random effect for participant within sequence. The geometric mean ratio (GMR) of boceprevir tablet to boceprevir capsule is presented with two-sided 90% CIs. Equivalence of formulations was signified by the GMR falling within prespecified bioequivalence bounds. | |
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Least Squares Geometric mean ratio |
| Estimated Value | 1.10 | |
| Confidence Interval |
(2-Sided) 95% 1.06 to 1.14 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Cmax of Boceprevir Tablets Versus Capsules in Fasted State |
|---|---|
| Description | Cmax is the highest plasma drug concentration observed on the plasma concentration-time curve. |
| Time Frame | Predose through 72 hours post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is per protocol; all available data are included in the model. No imputation is used for missing data. |
| Arm/Group Title | Boceprevir Tablets (Fasted) | Boceprevir Capsules (Fasted) |
|---|---|---|
| Arm/Group Description | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. |
| Measure Participants | 117 | 117 |
| Geometric Mean (90% Confidence Interval) [ng/mL] |
1263
|
1103
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Boceprevir Tablets (Fed), Boceprevir Capsules (Fed) |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Non-Inferiority or Equivalence | |
| Comments | Comparison of boceprevir tablet versus capsule used a mixed-effects model with fixed effects for formulation, sequence, and period, and a random effect for participant within sequence. The geometric mean ratio (GMR) of boceprevir tablet to boceprevir capsule is presented with two-sided 90% CIs. Equivalence of formulations was signified by the GMR falling within prespecified bioequivalence bounds. | |
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Least Squares Geometric mean ratio |
| Estimated Value | 1.15 | |
| Confidence Interval |
(2-Sided) 90% 1.09 to 1.21 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | AUC From Hour 0 to Infinity (AUCinf) in Fed State |
|---|---|
| Description | AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve. |
| Time Frame | Predose through 72 hours post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is per protocol; all available data are included in the model. No imputation is used for missing data. |
| Arm/Group Title | Boceprevir Tablets (Fed) | Boceprevir Capsules (Fed) |
|---|---|---|
| Arm/Group Description | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. |
| Measure Participants | 57 | 52 |
| Geometric Mean (90% Confidence Interval) [ng*hr/mL] |
7457
|
6879
|
| Title | AUCinf in Fasted State |
|---|---|
| Description | AUC is the measure of total plasma exposure of a drug over a given time period. AUC is derived from the area under the plasma drug concentration-time curve. |
| Time Frame | Predose through 72 hours post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is per protocol; all available data are included in the model. No imputation is used for missing data. |
| Arm/Group Title | Boceprevir Tablets (Fasted) | Boceprevir Capsules (Fasted) |
|---|---|---|
| Arm/Group Description | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. |
| Measure Participants | 94 | 84 |
| Geometric Mean (90% Confidence Interval) [ng*hr/mL] |
4534
|
4119
|
| Title | Half Life (t1/2) of Boceprevir in Fed State |
|---|---|
| Description | T1/2 is the time required for a given drug concentration to decrease by 50%. |
| Time Frame | Predose through 72 hours post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is per protocol; all available data are included in the model. No imputation is used for missing data. |
| Arm/Group Title | Boceprevir Tablets (Fed) | Boceprevir Capsules (Fed) |
|---|---|---|
| Arm/Group Description | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. |
| Measure Participants | 57 | 52 |
| Mean (Standard Deviation) [hours] |
1.61
(0.46)
|
1.46
(0.34)
|
| Title | t1/2 Boceprevir in Fasted State |
|---|---|
| Description | T1/2 is the time required for a given drug concentration to decrease by 50%. |
| Time Frame | Predose through 72 hours post-dose |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analysis is per protocol; all available data are included in the model. No imputation is used for missing data. |
| Arm/Group Title | Boceprevir Tablets (Fasted) | Boceprevir Capsules (Fasted) |
|---|---|---|
| Arm/Group Description | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. |
| Measure Participants | 93 | 82 |
| Mean (Standard Deviation) [hours] |
5.33
(0.73)
|
6.39
(0.84)
|
Adverse Events
| Time Frame | ||||||||
|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | In this study, participants received two single doses of boceprevir 800 mg, once as capsules and once as tablets, under fed and fasted conditions, in a crossover manner; adverse events were pooled as tablets (fed condition), capsules (fed condition), tablets (fasted condition), or capsules (fasted condition). | |||||||
| Arm/Group Title | Boceprevir Tablets (Fed) | Boceprevir Capsules (Fed) | Boceprevir Tablets (Fasted) | Boceprevir Capsules (Fasted) | ||||
| Arm/Group Description | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. | In Part 1 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 1 or Period 2 under fed conditions. | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in tablet formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. | In Part 2 of the study, participants received a single dose of boceprevir (800 mg) in capsule formulation in a cross-over manner during either Period 3 or Period 4 under fasted conditions. | ||||
All Cause Mortality |
||||||||
| Boceprevir Tablets (Fed) | Boceprevir Capsules (Fed) | Boceprevir Tablets (Fasted) | Boceprevir Capsules (Fasted) | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | / (NaN) | / (NaN) | ||||
Serious Adverse Events |
||||||||
| Boceprevir Tablets (Fed) | Boceprevir Capsules (Fed) | Boceprevir Tablets (Fasted) | Boceprevir Capsules (Fasted) | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/60 (0%) | 0/60 (0%) | 0/117 (0%) | 0/117 (0%) | ||||
Other (Not Including Serious) Adverse Events |
||||||||
| Boceprevir Tablets (Fed) | Boceprevir Capsules (Fed) | Boceprevir Tablets (Fasted) | Boceprevir Capsules (Fasted) | |||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 13/60 (21.7%) | 6/60 (10%) | 7/117 (6%) | 5/117 (4.3%) | ||||
| Gastrointestinal disorders | ||||||||
| Abdominal pain lower | 7/60 (11.7%) | 7 | 2/60 (3.3%) | 2 | 0/117 (0%) | 0 | 0/117 (0%) | 0 |
| Constipation | 5/60 (8.3%) | 6 | 4/60 (6.7%) | 4 | 7/117 (6%) | 7 | 5/117 (4.3%) | 5 |
| Reproductive system and breast disorders | ||||||||
| Menstruation irregular | 6/60 (10%) | 6 | 1/60 (1.7%) | 1 | 0/117 (0%) | 0 | 0/117 (0%) | 0 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication. The sponsor shall have the right to review and comment.
Results Point of Contact
| Name/Title | Vice President, Late Stage Development Group Leader |
|---|---|
| Organization | Merck Sharp & Dohme Corp |
| Phone | |
| ClinicalTrialsDisclosure@merck.com |
- P06992